Innate Pharma SA-Spons ADRIPHA
13F holders, Q3 2025 (September 30)9holders
1new positions
1sold out
1famous investor
$1.94avg. 13F price*
At the end of Q3 2025, 9 institutions reported holding Innate Pharma SA-Spons ADR (IPHA) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 1 sold out. The largest holders were Morgan Stanley ($103K), Citadel Advisors ($39K) and UBS Group AG ($9K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Innate Pharma SA-Spons ADR
- CUSIP
- 45781K204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $19 |
| Exits | 1 | $20K |
All 13F filers, Q2 2025 → Q3 2025: 2,350 shares bought and 20,571 shares sold, net −18,221 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Morgan Stanley | 0.00% | Add +4.6% | 53,564 | $103K |
| Citadel Advisors | 0.00% | Reduce -24.7% | 20,042 | $39K |
| UBS Group AG | 0.00% | Reduce -19.5% | 4,797 | $9K |
| GAMMA Investing LLC | 0.00% | Reduce -34.0% | 2,281 | $4K |
| Rhumbline Advisers | 0.00% | No change | 470 | $916 |
| Barclays PLC | 0.00% | No change | 307 | $593 |
| Optiver Holding B.V. | 0.00% | No change | 101 | $197 |
| Principal Securities, Inc. | 0.00% | No change | 45 | $87 |
| Farther Finance Advisors, LLC | 0.00% | New | 10 | $19 |
"% of holder's portfolio" is IPHA's weight in each manager's 13F, not the share of Innate Pharma SA-Spons ADR the manager owns.